Filgotinib for treating moderately to severely active Crohn's disease [ID6236]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mirikizumab for treating moderately to severely active Crohn's disease ID6244Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Risankizumab for previously treated moderately to severely active ulcerative colitis in people aged 16 and over ID6209Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC